Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Five biomarkers from one cerebrospinal fluid sample to stage Alzheimer’s disease

Staging Alzheimer’s disease on the basis of the disease’s biological underpinnings might help with stratification and prognostication, both in the clinical setting and in clinical trials. We propose a staging model based on only five biomarkers, which are related to amyloid-β and tau pathologies in different ways and can be measured with a single sample of cerebrospinal fluid.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: CSF staging model and hypothetical relationship with other pathological events during the AD continuum.


  1. Vogel, J. W. et al. Four distinct trajectories of tau deposition identified in Alzheimer’s disease. Nat. Med. 27, 871–881 (2021). In this paper, we described four different trajectories for tau deposition, which are useful for staging patients with AD.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Barthélemy, N. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat. Med. 26, 398–407 (2020). This paper reports that changes in the levels of site-specific tau phosphorylation occur at different stages of AD progression.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Salvadó, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med. 15, e2463 (2023). This paper reports the distinct correlation of tau biomarkers hyperphosphorylated at different epitopes with levels of Aβ plaques and tau tangles.

    Article  Google Scholar 

  4. Wesseling, H. et al. Tau PTM profiles identify patient heterogeneity and stages of Alzheimer’s disease. Cell 183, 1699–1713 (2020). This paper linked different post-translational tau modifications with different disease stages.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Young, A. L. et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nat. Commun. 9, 4273 (2018). This paper reports the derivation of SuStaIn, the data-driven model we used to create our staging model.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease. Nat. Med. 8, 1954–1963 (2023). This paper validates the CSF biomarker MTBR-tau243 in two independent cohorts and shows its tight correlation with tau tangle pathology.

    Article  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Salvadó, G. et al. Disease staging of Alzheimer’s disease using a CSF-based biomarker model. Nat. Aging (2024).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Five biomarkers from one cerebrospinal fluid sample to stage Alzheimer’s disease. Nat Aging 4, 623–624 (2024).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing